ABK Biomedical, Inc.

About ABK Biomedical, Inc.

ABK Biomedical is an innovative, clinical-stage medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, with a focus on improving outcomes for patients with liver tumors and cancer.

Products & Services

Eye90 microspheres®:A novel technology for Y90 radioembolization made with a proprietary, imageable glass composition for in-procedure visualization, currently an investigational product and not FDA-approved.

Easi-Vue™ embolic microspheres:Imageable bland embolization product allowing direct visualization at the target site, with FDA 510(k) clearance for the embolization of arteriovenous malformations and hypervascular tumors.

Specialties

Imageable Embolic Therapies Y90 Radioembolization Liver Tumor Treatment Hepatocellular Cancer Research Interventional Oncology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series D T: - FT: Series D	A: 35000000 MR: - FA: US$35 million FAN: 35000000	D: 2025-10-14 FD: 2025-10-14	5 investors

Series D Latest

2025-10-14

$35.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Aaron Berez

Board Chairman

M

Michael Mangano

President and CEO

LinkedIn (Pro only)

K

Ketan Patel

Director

J

James Eadie

Director

J

Joseph Siletto

Director

C

Carissa Bellardine Black

Director

View 15 more team members with Pro

Unlock Full Team Directory

Recent News